Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.55 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11279766 | 0.86 | CYP19A1 (0.67) | TBXAS1CYP19A1CYP11B1CYP11B2HMOX1 | |
| SCHEMBL1978472 | 0.81 | HMOX1 (0.68) | CYP19A1CYP11B1CYP11B2HMOX1 | |
| SCHEMBL11633201 | 0.81 | CYP19A1 (0.73) | CYP19A1CYP11B1CYP11B2HMOX1 | |
| SCHEMBL11756428 | 0.81 | CYP19A1 (0.53) | CYP19A1CYP11B1CYP11B2HMOX1 | |
| SCHEMBL11630824 | 0.81 | CYP19A1 (0.53) | CYP19A1CYP11B1CYP11B2HMOX1 | |
| SCHEMBL6981959 | 0.81 | CYP19A1 (0.73) | TBXAS1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL11632476 | 0.78 | KMT2A (0.54) | CYP19A1CYP11B1CYP11B2HMOX1 | |
| SCHEMBL6979413 | 0.78 | CYP19A1 (0.55) | TBXAS1CYP19A1CYP11B1CYP11B2L3MBTL1 | |
| SCHEMBL11363968 | 0.77 | CYP19A1 (0.58) | TBXAS1CYP19A1CYP11B1CYP11B2HMOX1 | |
| SCHEMBL11388108 | 0.76 | CYP19A1 (0.47) | TBXAS1CYP19A1HMOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030199530-A1 | New compounds derived from quinazoline | LES LABORATORIES SERVIER (FR) | 2003-10-23 | — | — | US | disclosed |
| EP-1346992-A1 | Quinazoline derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199530-A1 | New compounds derived from quinazoline | NQO2, XDH, DRD1 | TBXAS1 423/4885CYP19A1 1823/4885CYP11B1 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.